The CARM1-YIPF2 axis drives breast cancer progression and predicts poor prognosis.
- 1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, 42 Baiziting, Nanjing, 210009, China.
- 2Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, 42 Baiziting, Nanjing, 210009, China. Electronic address: [email protected].
- 3Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, 42 Baiziting, Nanjing, 210009, China. Electronic address: [email protected].
Abstract
Objective
To investigate the roles of CARM1 and its regulatory effect on YIPF2 in breast cancer progression.Methods
Breast cancer cells were transfected with CARM1 siRNA to knock down CARM1 expression. Cell proliferation, apoptosis, migration, and invasion were assessed using EdU, CCK-8, Annexin V/PI flow cytometry, wound-healing, and transwell assays, respectively. Co-expression of CARM1 and YIPF2 was evaluated using the GEPIA database and validated by qRT-PCR. Co-immunoprecipitation (Co-IP) was performed to assess the association between CARM1 and YIPF2, and asymmetric dimethylarginine (ADMA) signals in YIPF2 immunoprecipitates were assessed. Rescue experiments were performed following YIPF2 overexpression. In vivo studies were conducted to examine the anti-tumor effects of CARM1 inhibition.Results
We found that CARM1 was upregulated in breast cancer patients and cell lines. Higher CARM1 expression was associated with poorer survival. CARM1 knockdown inhibited proliferation, colony formation, migration, and invasion of breast cancer cells, and induced apoptosis. The correlation analysis indicated that CARM1 and YIPF2 were positively co-expressed. Co-IP experiments supported an association between CARM1 and YIPF2. CARM1 knockdown reduced the ADMA signal in YIPF2 immunoprecipitates, consistent with CARM1-dependent YIPF2 methylation. In addition, elevated YIPF2 predicted worse survival outcomes in breast cancer patients. Overexpression of YIPF2 partially rescued the suppression of tumor progression induced by CARM1 knockdown. Finally, tumors derived from sh-CARM1 cells were markedly smaller than those from control cells.Conclusion
Collectively, our findings support a role for CARM1 in breast cancer progression and provide evidence of its association with YIPF2 and CARM1-dependent YIPF2 methylation, offering insights into the CARM1-YIPF2 regulatory axis and potential therapeutic strategies.
Related
- Anatomical Heterogeneity in Longitudinal CA15-3 and CEA Rises Preceding Metastatic Breast Cancer Progression
- Pan-cancer multi-omics profiling of SRPK1 identifies tumour-specific associations with prognosis and predicted chemotherapy response in breast, colon and prostate cancer
- High glucose drives non-small cell lung cancer progression via OGT-mediated O-GlcNAcylation and PI3K/AKT/mTOR pathway activation.
- The RNA-binding protein KHSRP drives prostate cancer progression through a DUSP6 dependent axis
- BRD4-mediated histone H4K12 lactylation drives ovarian cancer progression by activating the Ube2v1-DDX3X ubiquitination axis
BibTeX
@article{gao2026carm1yipf2,
title = {{The CARM1-YIPF2 axis drives breast cancer progression and predicts poor prognosis.}},
author = {Xitao Gao and Shuchang Zhang and Wei Peng and Kun Xu},
journal = {Translational oncology},
year = {2026},
month = oct,
doi = {10.1016/j.tranon.2026.103073},
url = {https://europepmc.org/article/MED/42887062},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - The CARM1-YIPF2 axis drives breast cancer progression and predicts poor prognosis.
AU - Xitao Gao
AU - Shuchang Zhang
AU - Wei Peng
AU - Kun Xu
PY - 2026
DA - 2026/10/16
JO - Translational oncology
DO - 10.1016/j.tranon.2026.103073
UR - https://europepmc.org/article/MED/42887062
AB - Objective To investigate the roles of CARM1 and its regulatory effect on YIPF2 in breast cancer progression.Methods Breast cancer cells were transfected with CARM1 siRNA to knock down CARM1 expression. Cell proliferation, apoptosis, migration, and invasion were assessed using EdU, CCK-8, Annexin V/PI flow cytometry, wound-healing, and transwell assays, respectively. Co-expression of CARM1 and YIPF2 was evaluated using the GEPIA database and validated by qRT-PCR. Co-immunoprecipitation (Co-IP) was performed to assess the association between CARM1 and YIPF2, and asymmetric dimethylarginine (ADMA) signals in YIPF2 immunoprecipitates were assessed. Rescue experiments were performed following YIPF2 overexpression. In vivo studies were conducted to examine the anti-tumor effects of CARM1 inhibition.Results We found that CARM1 was upregulated in breast cancer patients and cell lines. Higher CARM1 expression was associated with poorer survival. CARM1 knockdown inhibited proliferation, colony formation, migration, and invasion of breast cancer cells, and induced apoptosis. The correlation analysis indicated that CARM1 and YIPF2 were positively co-expressed. Co-IP experiments supported an association between CARM1 and YIPF2. CARM1 knockdown reduced the ADMA signal in YIPF2 immunoprecipitates, consistent with CARM1-dependent YIPF2 methylation. In addition, elevated YIPF2 predicted worse survival outcomes in breast cancer patients. Overexpression of YIPF2 partially rescued the suppression of tumor progression induced by CARM1 knockdown. Finally, tumors derived from sh-CARM1 cells were markedly smaller than those from control cells.Conclusion Collectively, our findings support a role for CARM1 in breast cancer progression and provide evidence of its association with YIPF2 and CARM1-dependent YIPF2 methylation, offering insights into the CARM1-YIPF2 regulatory axis and potential therapeutic strategies.
SN - 1936-5233
ER -